21 May 2009
Human papillomavirus as a risk factor for development of cancer in allograft recipients
P Fiedor, Z Wierzbicki, K Pawelec, A Gardyszewska, T Łazowski, P Jurkowski, D Szubińska, K Szymańska, J Wojciula, A Wydrzyńska, M Socha, G Kowalska-Korczak, A Górski, M Durlik, L Pączek, S MajewskiAnn Transplant 2009; 14(1): 24-24 :: ID: 880286
Abstract
Background: Human papillomavirus (HPV) infection is the most common person-to-person transmitted viral infection and has a steadily increasing prevalence. The goal of this study was to evaluate the incidence of oncogenic type 16 HPV infections and development of cancer in patients after organ allotransplantation.
Material/Methods: 650 organ allograft recipients [kidney, kidney-pancreas, liver] transplanted between 1989 and 2003, receiving standard immunosuppressive treatment (CS, CsA, Tac and Aza), were followed for 2-15 years. Activity of specific receptors and mononuclear cells from peripheral blood was assessed and correlated with level of immunosuppression regiments. All patients were examined for the presence of HPV infection (confirmed by PCR).
Results: In 136 patients HPV16 oncogenic infection was found. Out of this number, in 22 patients (16.6%) skin and/or mucosal changes in anogenital area were found. Those patients were surgically treated and the diagnosis of cancer was confirmed by histopathology. The same type 16 of HPV was detected in the oral cavities. All recipients with clinical manifestation of HPV infection including patients with cancer showed abnormality and particularly lower activity of NK, CD4 and CD25 cell receptors. Immunosuppressive treatment was modified in these patients. Recurrence of cancer was observed in three patients 2-5 years after surgical treatment.
Conclusions: Long-term surviving organ allograft recipients with decreased
immune response and HPV infection have a high risk of neoplastic process
development in lower genital tract. Such patients should be carefully monitored and when such complication occurs surgical treatment is necessary with modification of immunosuppressive treatment.
Keywords: viral infections
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






